ImmunoPrecise Antibodies Leads Therapeutic Innovation with New Rabbit Antibody Developments

ImmunoPrecise Antibodies Ltd. (IPA), a leading AI-driven biotherapeutic research and technology company, has recently announced significant progress in the clinical development of rabbit monoclonal antibodies using its proprietary B Cell Select® platform. This development highlights IPA’s pioneering role as a Contract Research Organization (CRO) in creating high-quality therapeutic antibodies. The antibodies developed through this platform are currently advancing into clinical trials, showcasing their unique properties and potential in improving patient outcomes.

At the PEGS 2024 conference, OncoResponse Inc., a clinical-stage company, presented updates on two novel antibodies, OR502 and OR641, both discovered and refined using IPA's B Cell Select® platform. OR502, a humanized anti-leukocyte immunoglobulin-like receptor B2 (LILRB2) antibody, has entered Phase I/II clinical trials. It has shown an excellent safety profile and is being evaluated for its efficacy in treating advanced solid tumors. Preclinical models have demonstrated that OR502 is a best-in-class anti-LILRB2 antibody capable of reversing immunosuppression caused by myeloid cells in the tumor microenvironment (TME).

Meanwhile, OR641, another novel humanized dual antagonist antibody targeting both LILRB1 and LILRB2, has completed cell line development and is undergoing investigational new drug (IND)-enabling studies. Preclinical models have shown OR641's superior ability to reverse immunosuppression caused by both myeloid and lymphoid cells when compared to other anti-LILRB1/2 antibodies.

IPA’s B Cell Select® platform has significantly contributed to the rapid design and discovery of antibodies that have advanced to clinical stages for various clients. By preserving the natural structure of antibodies, this technology ensures optimal functionality in clinical settings. Through extensive testing and validation, the platform guarantees that these antibodies maintain their efficacy and reliability from the laboratory to the clinic.

Dr. Jennifer Bath, President and CEO of IPA, stated, "At ImmunoPrecise Antibodies, our mission is not just to develop antibodies but to redefine what’s possible in therapeutic interventions. Our innovative platform, built on years of expertise, has consistently delivered antibodies with superior qualities, many of which are now advancing in clinical trials." She emphasized the company's commitment to innovation and its strategic market advantage, supporting clients in bringing groundbreaking treatments to patients globally.

The Rabbit B Cell platform has been instrumental in the discovery process, excelling at generating high-affinity and highly specific rabbit monoclonal antibodies. This platform is meeting the market demand with very limited providers available. IPA has successfully utilized the B Cell Select platform in over 200 antibody programs, achieving remarkable success against various targets, including small molecules, peptides, and proteins. Building on this success, IPA now offers more complex therapeutic rabbit antibody campaigns, providing companies with greater flexibility in structuring their programs.

The field of rabbit monoclonal antibody therapeutics is rapidly advancing due to innovations in antibody engineering and humanization techniques. These advancements are making rabbit monoclonal antibodies increasingly popular for human therapeutic use. The unique properties of rabbit antibodies, combined with IPA’s comprehensive technologies, such as in silico humanization, indicate a strong potential for more rabbit-derived monoclonal antibodies to enter clinical trials and gain approval in the coming years. As this technology progresses, IPA remains at the forefront, harnessing these innovations to bring new, effective treatments to the clinic.

Dr. Kamal D. Puri, Chief Scientific Officer of OncoResponse, acknowledged IPA’s critical role in their success, praising the quality and reliability of IPA’s antibody discovery services. He stated, "We are thrilled to have worked with IPA to discover our lead therapeutic antibodies. The IPA team’s deep experience and expertise with a range of customized, high-throughput discovery strategies have played a critical role in the successful discovery of our molecules with unsurpassed speed and efficiency."

In summary, ImmunoPrecise Antibodies Ltd. continues to make significant strides in the development of therapeutic antibodies, particularly through its innovative B Cell Select® platform. With the successful clinical progression of antibodies like OR502 and OR641, the company is well-positioned to lead in the field of biotherapeutic research and technology, bringing groundbreaking treatments to patients worldwide.